TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10282583

Group type: EXPERIMENTAL
Intervention: Experimental group (drugs with computer-generated prompts)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no prompts)
Number of subjects: 10
Study: 29326087

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (3-month duration, focused on strength, balance, stretching exercises, and walking recommendations)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Number of subjects: 112

Group type: COMPARATOR
Intervention: Routine activities (Control Group)
Number of subjects: 112
Study: 26885697

Group type: EXPERIMENTAL
Intervention: AlgaeCal calcium supplement (AC)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group (n = 5070)
Number of subjects: 172
Study: 25470782

Group type: EXPERIMENTAL
Intervention: Pharmacist consultation (B1)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (B0)
Number of subjects: 135
Study: 22445192

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET) for 12 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sedentary lifestyle (control)
Number of subjects: 37
Study: 21989041

Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radial shockwave therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (Focused and Radial shockwave therapy)
Number of subjects: 0
Study: 17935212

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 985

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: IRT-6 subscale
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Maier Philipp subscale
Number of subjects: 985
Study: 16930211

Group type: EXPERIMENTAL
Intervention: Acamprosate (2 tablets of 333 mg t.i.d.)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19667667

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 300000
Study: 11124307

Group type: EXPERIMENTAL
Intervention: Fixed combination dorzolamide 2% and timolol 0.5% therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Concomitant administration of a topical beta-blocker and dorzolamide
Number of subjects: 74
Study: 9267375

Group type: EXPERIMENTAL
Intervention: Cytobrush and Ayre spatula
Number of subjects: 222

Group type: COMPARATOR
Intervention: Dacron swab and Ayre spatula
Number of subjects: 222
Study: 8228194

Group type: EXPERIMENTAL
Intervention: Severe sodium restriction (20 mmol/day)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Moderate sodium restriction (85 mmol/day)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (300 mmol/day sodium)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control (200 mmol/day sodium)
Number of subjects: 188
Study: 3027300

Group type: EXPERIMENTAL
Intervention: U-62,066E (2, 3, 4, 5, or 6 micrograms/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: U-62,066E
Number of subjects: 0
Study: 28992224

Group type: EXPERIMENTAL
Intervention: High cut‐off (HCO) dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium cut‐off (MCO) dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-flux (HF) dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro dialysis sera from HCO and MCO patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro dialysates from HCO and MCO
Number of subjects: 0
Study: 27788130

Group type: EXPERIMENTAL
Intervention: Placebo pill (Study 1, 2 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Placebo pill (Study 2, 3 months)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Duloxetine (Study 2, 3 months)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (Study 1)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo (Study 2)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Duloxetine (Study 2)
Number of subjects: 56
Study: 25022840

Group type: EXPERIMENTAL
Intervention: 17DD-YF vaccine subdose of 587 IU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17DD-YF vaccine subdose of 3,013 IU
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current dose of 17DD-YF vaccine (27,476 IU)
Number of subjects: 0
Study: 23082576

Group type: EXPERIMENTAL
Intervention: Essential oil dentifrice
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 104
Study: 15661551

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment (2 years)
Number of subjects: 564

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 564
Study: 12464864

Group type: EXPERIMENTAL
Intervention: Preoperative oral intake of a formula enriched with arginine and n‐3 fatty acids for 5 days before surgery (pre‐op group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Same preoperative treatment prolonged after surgery by jejunal infusion (peri‐op group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard isoenergetic, isonitrogenous formula for 5 days before surgery (control group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No supplementation before and after operation (conventional group)
Number of subjects: 200
Study: 9690720

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg o.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg b.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg t.d.s.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg o.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg t.d.s.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.d. and t.d.s.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.d. and t.d.s.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg t.d.s., 60 mg b.d. and 60 mg t.d.s.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Post-regimen serum gastrin values
Number of subjects: 32
Study: 8845493

Group type: EXPERIMENTAL
Intervention: Dose escalation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy management
Number of subjects: 0
Study: 2712613

Group type: EXPERIMENTAL
Intervention: Local steroids
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Combination treatment (local steroids + physiotherapy)
Number of subjects: 62
Study: 582550

Group type: EXPERIMENTAL
Intervention: Lithium sulphate (24‐36 mval/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28531361

Group type: EXPERIMENTAL
Intervention: EV 4 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: EV 9 mg
Number of subjects: 39

Group type: COMPARATOR
Intervention: EV 4 mg and EV 9 mg
Number of subjects: 39
Study: 28116437

Group type: EXPERIMENTAL
Intervention: Microabrasion before LED whitening
Number of subjects: 112

Group type: COMPARATOR
Intervention: Combined treatment of Beyond LED whitening and fluoride removal agent
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 24955610

Group type: EXPERIMENTAL
Intervention: 12-month lifestyle plus metformin intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (adolescents who increased their %BF)
Number of subjects: 56
Study: 22782367

Group type: EXPERIMENTAL
Intervention: Prophylactic large‐pore lightweight mesh
Number of subjects: 36

Group type: COMPARATOR
Intervention: No mesh (control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subcutaneous fat thickness ≥23 mm
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Insertion of a mesh
Number of subjects: 36
Study: 20103777

Group type: EXPERIMENTAL
Intervention: Hypokalemia (serum potassium <4 mEq/L)
Number of subjects: 2793

Group type: COMPARATOR
Intervention: Normokalemia (4 to 4.9 mEq/L)
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Mild hypokalemia (3.5 to 3.9 mEq/L)
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Hypokalemia (<4 mEq/L)
Number of subjects: 2793
Study: 20409883

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16131699

Group type: EXPERIMENTAL
Intervention: High glycemic index (HGI) meal
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low glycemic index (LGI) meal
Number of subjects: 8
Study: 11911511

Group type: EXPERIMENTAL
Intervention: Axilla hold
Number of subjects: 22

Group type: COMPARATOR
Intervention: Distal hold
Number of subjects: 22
Study: 10430251

Group type: EXPERIMENTAL
Intervention: XRT (breast irradiation)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Control (no XRT)
Number of subjects: 623
Study: 7776510

Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: buprenorphine 5 micrograms in 1 ml of 0.25% bupivacaine (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: buprenorphine 8 micrograms in 1 ml of 0.25% bupivacaine (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: buprenorphine 12 micrograms in 1 ml of 0.25% bupivacaine (group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: buprenorphine 15 micrograms in 1 ml of 0.25% bupivacaine (group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: buprenorphine 18 micrograms in 1 ml of 0.25% bupivacaine (group F)
Number of subjects: 60
Study: 2335446

Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 378140

Group type: EXPERIMENTAL
Intervention: Perioperative administration of cefamandole plus five days of placebo
Number of subjects: 220

Group type: COMPARATOR
Intervention: Perioperative plus five days of postoperative antibiotic therapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Perioperative therapy alone
Number of subjects: 220

Group type: COMPARATOR
Intervention: Perioperative plus 5-7 days of postoperative treatment
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Postoperative infection
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Appropriate prophylactic antibiotic
Number of subjects: 220
Study: 31741356

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1640
Study: 25347930

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide mucoadhesive film
Number of subjects: 60

Group type: COMPARATOR
Intervention: Licorice mucoadhesive film
Number of subjects: 60
Study: 25394316

Group type: EXPERIMENTAL
Intervention: Roland-Morris Disability Questionnaire (RMDQ)
Number of subjects: 457
Study: 23351013

Group type: EXPERIMENTAL
Intervention: MMF withdrawal (2 g/d)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CsA withdrawal
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MMF group
Number of subjects: 39

Group type: COMPARATOR
Intervention: CsA group
Number of subjects: 39
Study: 21069309

Group type: EXPERIMENTAL
Intervention: 2 mg tolterodine (twice a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Watchful waiting (control group)
Number of subjects: 80
Study: 19587891

Group type: EXPERIMENTAL
Intervention: Fluor Kin antisarro dentifrice (0.32% sodium fluoride, 4.1% tetrapotassium pyrophosphate, 2.0% PVM/MA copolymer, 1.0% provitamin B5, 0.2% vitamin B3) used twice a day for 2 minutes for 3 months
Number of subjects: 48
Study: 17459739

Group type: EXPERIMENTAL
Intervention: Oxatomide treatment for 6 months
Number of subjects: 14

Group type: COMPARATOR
Intervention: Medication-free lead-in period for 3 months
Number of subjects: 14
Study: 16316358

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (300 mg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11152855

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9624242

Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (cisplatin and etoposide)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 58
Study: 7828190

Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan (group I)
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo (group II)
Number of subjects: 1246

Group type: EXPERIMENTAL
Intervention: 100 mg oral sumatriptan (group I) for treating headache recurrence
Number of subjects: 1246

Group type: COMPARATOR
Intervention: Placebo (group II) for treating headache recurrence
Number of subjects: 1246
Study: 3254614

Group type: EXPERIMENTAL
Intervention: Glucagon (0.25, 0.5, 1.0, or 2.0 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: G-(1-21) (0.175, 0.35, 0.70, or 1.4 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29658845

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 26091812

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft surgery (OPCABG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass graft surgery (ONCABG)
Number of subjects: 0
Study: 26218935

Group type: EXPERIMENTAL
Intervention: Whitacre needle
Number of subjects: 149

Group type: COMPARATOR
Intervention: Quincke needle
Number of subjects: 149
Study: 23939351

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (Hb trigger, 70 g/L; target, 71-90 g/L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (Hb trigger, 90 g/L; target, 91-110 g/L)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Overall comparison of restrictive vs liberal
Number of subjects: 100
Study: 20888255

Group type: EXPERIMENTAL
Intervention: Blood cardioplegia (Group 2)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (Group 1)
Number of subjects: 47
Study: 19180322

Group type: EXPERIMENTAL
Intervention: SRP+Loxoprofen
Number of subjects: 60

Group type: COMPARATOR
Intervention: SRP+placebo
Number of subjects: 60
Study: 16600984

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1500 mg/m²) followed by oxaliplatin (85 mg/m²) on day 1 and 15 of a 28-day cycle
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gemcitabine-oxaliplatin (GEMOX) combination
Number of subjects: 30
Study: 12744112

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel (harmonic scalpel)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 142
Study: 11001084

Group type: EXPERIMENTAL
Intervention: Specialist asthma nurse intervention with three 6-weekly outpatient appointments for structured asthma consultation.
Number of subjects: 211
Study: 8644382

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 80

Group type: COMPARATOR
Intervention: Myelography
Number of subjects: 80
Study: 1993640

Group type: EXPERIMENTAL
Intervention: Zolpidem 5 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolpidem 15 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 6418188

Group type: EXPERIMENTAL
Intervention: Alfentanil with Althesin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Etomidate or Fentanyl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Althesin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ease of maintenance of anaesthesia
Number of subjects: 80
Study: 30672056

Group type: EXPERIMENTAL
Intervention: Magee Equations
Number of subjects: 175

Group type: COMPARATOR
Intervention: No Magee Equations
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Magee Equations and Ki67 availability
Number of subjects: 175

Group type: COMPARATOR
Intervention: No Magee Equations and Ki67 availability
Number of subjects: 175
Study: 30321007

Group type: EXPERIMENTAL
Intervention: Risk-stratified screening strategy considering family history, breast density, and genetic variants.
Number of subjects: 85000

Group type: COMPARATOR
Intervention: Standard age-based screening programs recommended by the European Union.
Number of subjects: 85000
Study: 27846839

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-treatment
Number of subjects: 100
Study: 25349017

Group type: EXPERIMENTAL
Intervention: Shared Care (SC)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 700
Study: 22253323

Group type: EXPERIMENTAL
Intervention: Exercise plus group-based self-regulatory skills intervention
Number of subjects: 43
Study: 20962793

Group type: EXPERIMENTAL
Intervention: Oral erectile medications (specific medications not mentioned), administered for two 3-month phases.
Number of subjects: 50
Study: 17363761

Group type: EXPERIMENTAL
Intervention: Self-affirmation (thought of personal strengths)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secure attachment prime (thought of a close, caring relationship)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High Appearance-RS individuals thinking about negative aspects of their appearance
Number of subjects: 0
Study: 16216977

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering drugs (thiazides, β-blockers, ACE inhibitors, angiotensin II receptor antagonists)
Number of subjects: 24644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24644

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering drugs (all classes)
Number of subjects: 24644
Study: 11268707

Group type: EXPERIMENTAL
Intervention: Eflornithine HCl 13.9% cream
Number of subjects: 315

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 315

Group type: COMPARATOR
Intervention: Sodium lauryl sulphate
Number of subjects: 315
Study: 9834591

Group type: EXPERIMENTAL
Intervention: Continuous TIVA with propofol, ketamine, and vecuronium in combination with butorphanol (PKBt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous TIVA with propofol, ketamine, and vecuronium in combination with buprenorphine (PKBp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elderly patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with long anesthetic time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with general anesthesia combined with epidural anesthesia
Number of subjects: 0
Study: 8006923

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 47
Study: 2689472

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (10, 30, or 90 mg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (combined doses)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 4603994

Group type: EXPERIMENTAL
Intervention: Intradermal cholera vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous cholera vaccine
Number of subjects: 0
Study: 448844

Group type: EXPERIMENTAL
Intervention: Cefazolin sodium, 500 mg intramuscularly twice daily
Number of subjects: 82

Group type: COMPARATOR
Intervention: Penicillin G procaine, 600,000 units intramuscularly twice daily
Number of subjects: 82
Study: 30654479

Group type: EXPERIMENTAL
Intervention: Personalized dietary consultations
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo dietary supplement (fruit juice)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Personalized dietary consultations plus placebo fruit juice
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (including waitlist control)
Number of subjects: 60
Study: 29190727

Group type: EXPERIMENTAL
Intervention: Training program with an upper-limb prosthesis simulator
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham training (dummy training without the prosthesis simulator)
Number of subjects: 71

Group type: COMPARATOR
Intervention: No training at all
Number of subjects: 71
Study: 25397864

Group type: EXPERIMENTAL
Intervention: Active laser treatment (NIR light therapy) with a cumulative dose of 360 J
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 39
Study: 24952882

Group type: EXPERIMENTAL
Intervention: Ultra Corega cream tasteless
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ultra Corega powder tasteless
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no denture adhesive)
Number of subjects: 40
Study: 21975275

Group type: EXPERIMENTAL
Intervention: Tiotropium plus FSC (250/50 μg twice daily)
Number of subjects: 479

Group type: EXPERIMENTAL
Intervention: Tiotropium plus FSC (250/50 μg twice daily) in GOLD stage II patients
Number of subjects: 479
Study: 19321268

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17320747

Group type: EXPERIMENTAL
Intervention: Gothic arch type
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Height/width ratio (H/W)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Romanesque arch geometry
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control subjects (N=63)
Number of subjects: 63
Study: 15341353

Group type: EXPERIMENTAL
Intervention: Polydioxanon barrier (test group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Polylactide acetyltributyl citrate barrier (control group)
Number of subjects: 15
Study: 11313504

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol using metered dose inhaler via commercial spacer device (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inhaled salbutamol using metered dose inhaler via improvised spacer device (Group II)
Number of subjects: 60
Study: 9492970

Group type: EXPERIMENTAL
Intervention: Low-fat eating pattern
Number of subjects: 64500

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 64500

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (CaD)
Number of subjects: 64500

Group type: COMPARATOR
Intervention: Control group (women not enrolled in CT components)
Number of subjects: 64500